Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Balzarotti

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|October 21, 2003
Idiopathic thrombocytopenic purpura and splenic marginal-zone B-cell lymphoma: a casual correlation?Massimo Magagnoli, Monica Balzarotti, Luca Castagna, et al.
Anti-Cancer Drugs|August 18, 2021
Risk-tailored treatment of splenic marginal zone lymphomaRoberto Castelli, Monica Balzarotti, Emanuele Salvi, et al.
Leukemia & Lymphoma|October 19, 2007
High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphomaMassimo Magagnoli, Monica Balzarotti, Licia Vanessa Siracusano, et al.
European Journal of Haematology|January 27, 2007
Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusionElisabetta Todisco, Luca Castagna, Barbara Sarina, et al.
American Journal of Hematology|July 25, 2003
Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institutionMassimo Magagnoli, Luca Castagna, Monica Balzarotti, et al.
Haematologica|September 18, 2025
Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphomaArmando Santoro, Ciro Maria Improta, Barbara Sarina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective studyAlexia Bertuzzi, Luca Castagna, Andrea Nozza, et al.
American Journal of Hematology|October 5, 2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective studyLuca Castagna, Massimo Magagnoli, Monica Balzarotti, et al.
European Journal of Haematology|February 23, 2007
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patientsElisabetta Todisco, Luca Castagna, Barbara Sarina, et al.
Haematologica|January 19, 2007
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphomaArmando Santoro, Massimo Magagnoli, Michele Spina, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|October 21, 2003
Idiopathic thrombocytopenic purpura and splenic marginal-zone B-cell lymphoma: a casual correlation?Massimo Magagnoli, Monica Balzarotti, Luca Castagna, et al.
Anti-Cancer Drugs|August 18, 2021
Risk-tailored treatment of splenic marginal zone lymphomaRoberto Castelli, Monica Balzarotti, Emanuele Salvi, et al.
Leukemia & Lymphoma|October 19, 2007
High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphomaMassimo Magagnoli, Monica Balzarotti, Licia Vanessa Siracusano, et al.
European Journal of Haematology|January 27, 2007
Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusionElisabetta Todisco, Luca Castagna, Barbara Sarina, et al.
American Journal of Hematology|July 25, 2003
Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institutionMassimo Magagnoli, Luca Castagna, Monica Balzarotti, et al.
Haematologica|September 18, 2025
Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphomaArmando Santoro, Ciro Maria Improta, Barbara Sarina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective studyAlexia Bertuzzi, Luca Castagna, Andrea Nozza, et al.
American Journal of Hematology|October 5, 2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective studyLuca Castagna, Massimo Magagnoli, Monica Balzarotti, et al.
European Journal of Haematology|February 23, 2007
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patientsElisabetta Todisco, Luca Castagna, Barbara Sarina, et al.
Haematologica|January 19, 2007
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphomaArmando Santoro, Massimo Magagnoli, Michele Spina, et al.
Pageof 8